Genmab A/S (NASDAQ:GMAB) Receives $39.17 Average PT from Brokerages

Shares of Genmab A/S (NASDAQ:GMAB - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the thirteen analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $39.17.

Several equities analysts have recently weighed in on the company. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Truist Financial cut their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Wall Street Zen cut shares of Genmab A/S from a "buy" rating to a "hold" rating in a report on Friday, June 6th. Finally, Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a report on Thursday, February 13th.

Institutional Investors Weigh In On Genmab A/S

Hedge funds have recently added to or reduced their stakes in the stock. ABC Arbitrage SA bought a new stake in shares of Genmab A/S in the fourth quarter worth $3,692,000. Cromwell Holdings LLC boosted its position in Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after purchasing an additional 2,496 shares during the last quarter. Y Intercept Hong Kong Ltd grew its stake in shares of Genmab A/S by 371.0% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 73,696 shares of the company's stock valued at $1,538,000 after purchasing an additional 58,048 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Genmab A/S by 4.0% during the 4th quarter. Bank of New York Mellon Corp now owns 71,623 shares of the company's stock valued at $1,495,000 after purchasing an additional 2,749 shares during the period. Finally, AIMZ Investment Advisors LLC purchased a new stake in shares of Genmab A/S during the 4th quarter valued at about $3,525,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Price Performance

NASDAQ:GMAB traded down $0.27 during mid-day trading on Friday, hitting $22.82. 1,112,723 shares of the company's stock were exchanged, compared to its average volume of 1,165,267. The company has a market cap of $14.63 billion, a PE ratio of 13.11, a P/E/G ratio of 2.65 and a beta of 0.96. Genmab A/S has a one year low of $17.24 and a one year high of $28.56. The business has a fifty day moving average price of $20.46 and a 200 day moving average price of $20.73.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. The firm had revenue of $715.00 million for the quarter, compared to analysts' expectations of $5.17 billion. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, equities analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.